Drug Trial Radar · NCT03181984
Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Last checked: Nov 19, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Aug 31, 2017
Primary completion
Apr 19, 2023
Study completion Apr 19, 2023
Sponsor
- Lead sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.
Conditions
- Port-Wine Stain
Interventions
HemoporfinDrug
Hemoporfin mediated photodynamic therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse eventsTime frame: 96 weeks after hemoporfin application
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
PLA Army General Hospital
Beijing, China
Shanghai Dermatology Hospital
Shanghai, China
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine
Shijiazhuang, Herbei, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.